CRISPR's bottleneck is delivery, not the editors
“这在临床医学中尤其是个问题：能够编辑脑细胞、心脏细胞或肌肉细胞具有巨大潜力，但目前我们并没有把这些编辑工具送入那些细胞的工具，”杜德纳说。“我们有编辑器，只是不知道如何把它们送到需要去的地方。”
English original
"This is especially an issue in clinical medicine where being able to edit brain cells, heart cells or muscle cells has incredible potential but right now we don't really have the tools to introduce the editors into those cells," Doudna said. "We have the editors; we just don't know how to get them where they need to go."
在6月中旬CNBC全球进化峰会上
报道摘要
CRISPR gene editing, which slices DNA to treat diseases, had its first-ever systemic delivery in a human body. Jennifer Doudna, who won the 2020 Nobel Prize in chemistry for her work on CRISPR, called ...
CNBC